Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT)
Inge Ubink(Heidelberg University), Inne H.M. Borel Rinkes(Utrecht University), Onno Kranenburg(Utrecht University), Y. C. W. Holierhoek(Meander Medisch Centrum), Wilhelmina M. U. van Grevenstein(University Medical Center Utrecht), Haiko J. Bloemendal(Meander Medisch Centrum), Miriam Koopman(Utrecht University), MP Schwartz(Meander Medisch Centrum), Menno A. Brink, Ron H.J. Mathijssen(Erasmus MC), Sjoerd G. Elias(Utrecht University), Martijn P. Lolkema(National Institutes of Health), Wendy W.J. de Leng(University of Pittsburgh), Anneroos W. Boerman(Meander Medisch Centrum), Roel A. de Weger(Utrecht University), Paul M. Verheijen(Meander Medisch Centrum)
Cited by 14
Related Papers
Natural adjuvants: Endogenous activators of dendritic cells
|Nature Medicine|1999|1.6k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
|PubMed|2001|752
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|732
The Translational Landscape of the Human Heart
|Cell|2019|681